| 1. Gibson K, Wood R, Oldham A, Major J. (1993) The synthesis of heterosubstituted benzimidazole derivatives with potent angiotensin II antagonist activity, 3 (6): [10.1016/S0960-894X(00)80279-6] |
| 2. Reitz DB, Penick MA, Reinhard EJ, Cheng BK, Olins GM, Corpus VM, Palomo MA, McGraw DE, McMahon EG. (1994) 1H-1,2,4-triazole angiotensin II receptor antagonists: N-phenylpyridinylmethyl and N-pyridinylphenylmethyl analogs of SC-50560, 4 (1): [10.1016/S0960-894X(01)81129-X] |
| 3. Bovy PR, Reitz DB, Collins JT, Chamberlain TS, Olins GM, Corpus VM, McMahon EG, Palomo MA, Koepke JP, Smits GJ.. (1993) Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists., 36 (1): [PMID:8421274] [10.1021/jm00053a013] |
| 4. Weller HN, Miller AV, Moquin RV, Dickinson KE, Hedberg S, Moreland S, Cohen RB, Delaney CL, Skwish S, Williams S. (1992) Benzothiadiazine dioxides: A new class of potent angiotensin-II (AT1) receptor antagonists, 2 (9): [10.1016/S0960-894X(00)80630-7] |
| 5. Levin J, Venkatesan A, Chan P, Baker J, Francisco G, Bailey T, Vice G, Katocs A, Lai F, Coupet J. (1994) 2,3,6-Substituted quinazolinones as angiotensin II receptor antagonists, 4 (9): [10.1016/S0960-894X(01)80243-2] |
| 6. Levin JI, Chan PS, Bailey T, Katocs AS, Venkatesan A. (1994) The synthesis of 2,3-dihydro-4(1H)-quinazolinone angiotensin II receptor antagonists, 4 (9): [10.1016/S0960-894X(01)80244-4] |
| 7. Chang L, Ashton W, Flanagan K, Naylor E, Chakravarty P, Patchett A, Greenlee W, Bendesky R, Chen T, Faust K, Kling P, Schaffer L, Schorn T, Zingaro G, Chang R, Lotti V, Kivlighn S, Siegl P. (1994) Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide, 4 (1): [10.1016/S0960-894X(01)81132-X] |
| 8. Bradbury RH, Allott CP, Dennis M, Girdwood JA, Kenny PW, Major JS, Oldham AA, Ratcliffe AH, Rivett JE, Roberts DA.. (1993) New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives., 36 (9): [PMID:8487261] [10.1021/jm00061a016] |
| 9. Dorsch D, Mederski WW, Beier N, Lues I, Minck K, Schelling P. (1994) (6-oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonists, 4 (11): [10.1016/S0960-894X(01)80348-6] |
| 10. Bantick JR, Beaton HG, Cooper SL, Hill S, Hirst SC, McInally T, Spencer J, Tinker AC, Willis PA. (1994) New non-peptide angiotensin II receptor antagonists. 2: structure - activity relationship of a series of annelated 2(1H)-pyridinones, 4 (1): [10.1016/S0960-894X(01)81134-3] |
| 11. Bradbury R, Edwards M, Fisher E, Girdwood J, Major J, Oldham A, Patel M, Pearce R, Revill J, Ratcliffe A. (1994) New nonpeptide angiostensin II receptor antagonists. Synthesis, biological properties and structure-activity relationships of 3-substituted 2,6-dialkyl-4-(biphenyll)methylaminopyridine derivatives., 4 (1): [10.1016/S0960-894X(01)81136-7] |
| 12. Levin J, Chan P, Coupet J, Bailey T, Vice G, Thibault L, Lai F, Venkatesan A, Cobuzzi A. (1994) 6-isoxazolinyl and isoxazolidinyl substituted quinazolinones as angiotensin II receptor antagonists, 4 (14): [10.1016/S0960-894X(00)80365-0] |
| 13. Levin JI, Chan PS, Coupet J, Thibault L, Venkatesan A, Bailey TK, Vice G, Cobuzzi A, Lai F, Mellish N. (1994) Synthesis and biological evaluation of the potent isoxazolidinyl angiotensin II receptor antagonist CL332,877 and its enantiomers., 4 (14): [10.1016/S0960-894X(00)80366-2] |
| 14. Sircar I, Winters RT, Quin J, Lu GH, Major TC, Panek RL.. (1993) Nonpeptide angiotensin II receptor antagonists. 1. Synthesis and in vitro structure-activity relationships of 4-[[[(1H-pyrrol-1-ylacetyl)amino]phenyl]methyl]imidazole derivatives as angiotensin II receptor antagonists., 36 (12): [PMID:8510101] [10.1021/jm00064a007] |
| 15. Zydowsky TM, Winn M, De B, Condon SL, Altenbach RJ, Basha FZ, Boyd SA, Buckner SA, Hancock AA, Lee JY, Mantei RA, Novosad EI, Sorensen BK, Tasker AS, Shiosaki K, Kerkman DJ, Opgenorth TJ, DeBernardis JF. (1994) Synthesis and In Vitro evaluation of fused ring heterocyle-containing angiotensin II antagonists., 4 (1): [10.1016/S0960-894X(01)81142-2] |
| 16. Murray W, Lalan P, Gill A, Addo M, Lewis J, Lee D, Rampulla R, Wachter M, Hsi J, Underwood D. (1992) Substituted piperidin-2-one biphenyltetrazoles as angiotensin II antagonists, 2 (12): [10.1016/S0960-894X(00)80474-6] |
| 17. Estenne G, Dodey P, Renaut P, Leclerc G. (1995) Synthesis and biological evaluation of new arylthiophene analogs of DuP 753, 5 (1): [10.1016/0960-894X(94)00451-K] |
| 18. Yanagisawa H, Amemiya Y, Kanazaki T, Fujimoto K, Shimoji Y, Fujimoto Y, Sada T, Mizuno M, Koike H. (1994) Angiotensin II receptor antagonists: imidazoles and pyrroles bearing hydroxymethyl and carboxy substituents, 4 (1): [10.1016/S0960-894X(01)81143-4] |
| 19. Levin J, Venkatesan A, Chan P, Bailey T, Vice G, Coupet J. (1994) 6-Substituted Quinazolinone Angiotensin II Receptor Antagonists, 4 (15): [10.1016/S0960-894X(01)80377-2] |
| 20. Venkatesan A, Levin J, Baker J, Chan P, Bailey T, Coupet J. (1994) Substituted 4H-pyrido[1,2-a]pyrimidin-4-one angiotensin II receptor antagonists., 4 (1): [10.1016/S0960-894X(01)81144-6] |
| 21. Kohara Y, Imamiya E, Kubo K, Wada T, Inada Y, Naka T. (1995) A new class of angiotensin II receptor antagonists with a novel acidic bioisostere, 5 (17): [10.1016/0960-894X(95)00319-O] |
| 22. Ryono D, Lloyd J, Poss M, Bird J, Buote J, Chong S, Dejneka T, Dickinson K, Gu Z, Mathers P, Moreland S, Morrison R, Petrillo E, Powell J, Schaeffer T, Spitzmiller E, White R. (1994) Orally active prodrugs of quinoline-4-carboxylic acid angiotensin II receptor antagonists, 4 (1): [10.1016/S0960-894X(01)81147-1] |
| 23. Dorsch D, Mederski WW, Osswald M, Beier N, Schelling P. (1995) Uracil-based angiotensin II receptor antagonists, 5 (18): [10.1016/0960-894X(95)00370-9] |
| 24. Miyake K, Matsukura M, Yoneda N, Hiroshima O, Mori N, Ishihara H, Musha T, Matsuoka T, Shoji T, Minami N, Hamano S, Saito I. (1994) Discovery and development of aryl-fused imidazole-based angiotensin II antagonists, 4 (1): [10.1016/S0960-894X(01)81149-5] |
| 25. Huang HC, Reitz DB, Chamberlain TS, Olins GM, Corpus VM, McMahon EG, Palomo MA, Koepke JP, Smits GJ, McGraw DE.. (1993) Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists., 36 (15): [PMID:8340920] [10.1021/jm00067a015] |
| 26. Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, Rodríguez R, Carceller E, García-Rafanell J, Forn J.. (1996) Diphenylpropionic acids as new AT1 selective angiotensin II antagonists., 39 (11): [PMID:8667363] [10.1021/jm9508853] |
| 27. Sircar I, Hodges JC, Quin J, Bunker AM, Winters RT, Edmunds JJ, Kostlan CR, Connolly C, Kesten SJ, Hamby JM.. (1993) Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)., 36 (16): [PMID:8360871] [10.1021/jm00068a002] |
| 28. Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T.. (1993) Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids., 36 (16): [PMID:8360879] [10.1021/jm00068a011] |
| 29. Nicolaï E, Curé G, Goyard J, Kirchner M, Teulon JM, Versigny A, Cazes M, Caussade F, Virone-Oddos A, Cloarec A.. (1994) Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists., 37 (15): [PMID:8057285] [10.1021/jm00041a016] |
| 30. Duncia JV, Santella JB, Chiu AT, Wong PC, Wexler RR. (1995) Dibenzobicyclo[2.2.2.]octane angiotensin II receptor antagonists, 5 (3): [10.1016/0960-894X(95)00017-N] |
| 31. Carini DJ, Duncia JV, Aldrich PE, Chiu AT, Johnson AL, Pierce ME, Price WA, Santella JB, Wells GJ, Wexler RR.. (1991) Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives., 34 (8): [PMID:1875348] [10.1021/jm00112a031] |
| 32. Chang LL, Ashton WT, Flanagan KL, Strelitz RA, MacCoss M, Greenlee WJ, Chang RS, Lotti VJ, Faust KA, Chen TB.. (1993) Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones., 36 (17): [PMID:8355255] [10.1021/jm00069a015] |
| 33. Cappelli A, Pericot Mohr Gl Gl, Gallelli A, Rizzo M, Anzini M, Vomero S, Mennuni L, Ferrari F, Makovec F, Menziani MC, De Benedetti PG, Giorgi G.. (2004) Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure., 47 (10): [PMID:15115399] [10.1021/jm031100t] |
| 34. Huang H, Chamberlain TS, Olins GM, Corpus VM, Chen ST, McMahon EG, Palomo MA, Blaine EH, Manning RE. (1994) Discovery of nonpeptide potent conformationally restricted angiotensin II receptor antagonists, 4 (21): [10.1016/S0960-894X(01)80290-0] |
| 35. Thomas AP, Roberts DA, Thomason DA. (1994) The synthesis and biological activity of tetrahydroquinoline angiotensin II antagonists containing a substituted biphenyltetrazole group, 4 (21): [10.1016/S0960-894X(01)80295-X] |
| 36. Roumelioti P, Polevaya L, Zoumpoulakis P, Giatas N, Mutule I, Keivish T, Zoga A, Vlahakos D, Iliodromitis E, Kremastinos D, Grdadolnik SG, Mavromoustakos T, Matsoukas J.. (2002) Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists., 12 (18): [PMID:12182875] [10.1016/s0960-894x(02)00474-2] |
| 37. Lin HS, Rampersaud AA, Zimmerman K, Steinberg MI, Boyd DB.. (1992) Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity., 35 (14): [PMID:1635064] [10.1021/jm00092a017] |
| 38. Winn M, De B, Zydowsky TM, Altenbach RJ, Basha FZ, Boyd SA, Brune ME, Buckner SA, Crowell D, Drizin I.. (1993) 2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists., 36 (18): [PMID:8410980] [10.1021/jm00070a012] |
| 39. Ashton WT, Chang LL, Flanagan KL, Hutchins SM, Naylor EM, Chakravarty PK, Patchett AA, Greenlee WJ, Chen TB, Faust KA.. (1994) Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity., 37 (17): [PMID:8064808] [10.1021/jm00043a020] |
| 40. Mantlo NB, Chakravarty PK, Ondeyka DL, Siegl PK, Chang RS, Lotti VJ, Faust KA, Chen TB, Schorn TW, Sweet CS.. (1991) Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists., 34 (9): [PMID:1895308] [10.1021/jm00113a035] |
| 41. Harmat NJ, Giorgi R, Bonaccorsi F, Cerbai G, Colombani SM, Renzetti AR, Cirillo R, Subissi A, Alagona G, Ghio C.. (1995) 4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization., 38 (15): [PMID:7636853] [10.1021/jm00015a015] |
| 42. Bühlmayer P, Criscione L, Fuhrer W, Furet P, de Gasparo M, Stutz S, Whitebread S.. (1991) Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives., 34 (10): [PMID:1920360] [10.1021/jm00114a021] |
| 43. Judd DB, Dowle MD, Middlemiss D, Scopes DI, Ross BC, Jack TI, Pass M, Tranquillini E, Hobson JE, Panchal TA.. (1994) Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability., 37 (19): [PMID:7932534] [10.1021/jm00045a016] |
| 44. Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y, Koike H.. (1996) Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds., 39 (1): [PMID:8568823] [10.1021/jm950450f] |
| 45. Bernhart CA, Perreaut PM, Ferrari BP, Muneaux YA, Assens JL, Clément J, Haudricourt F, Muneaux CF, Taillades JE, Vignal MA.. (1993) A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists., 36 (22): [PMID:8230127] [10.1021/jm00074a018] |
| 46. Buhlmayer P, Furet P, Criscione L, de Gasparo M, Whitebread S, Schmidlin T, Lattmann R, Wood J. (1994) Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series, 4 (1): [10.1016/S0960-894X(01)81117-3] |
| 47. Leung D, Abbenante G, Fairlie DP.. (2000) Protease inhibitors: current status and future prospects., 43 (3): [PMID:10669559] [10.1021/jm990412m] |
| 48. Ashton WT, Hutchins SM, Greenlee WJ, Doss GA, Chang RS, Lotti VJ, Faust KA, Chen TB, Zingaro GJ, Kivlighn SD.. (1993) Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates., 36 (23): [PMID:8246227] [10.1021/jm00075a014] |
| 49. De B, Winn M, Zydowsky TM, Kerkman DJ, DeBernardis JF, Lee J, Buckner S, Warner R, Brune M, Hancock A.. (1992) Discovery of a novel class of orally active, non-peptide angiotensin II antagonists., 35 (20): [PMID:1433184] [10.1021/jm00098a018] |
| 50. Murray W, Lalan P, Gill A, Addo M, Lewis J, Lee D, Wachter M, Rampulla R, Underwood D. (1993) Substituted pyrrolidin-2-one biphenyltetrazoles as angiotensin II antagonists, 3 (2): [10.1016/S0960-894X(01)80914-8] |
| 51. Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Chakravarty PK, Patchett AA.. (1993) (Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists., 36 (23): [PMID:8246245] [10.1021/jm00075a033] |
| 52. Chang LL, Ashton WT, Flanagan KL, Chen TB, O'Malley SS, Zingaro GJ, Kivlighn SD, Siegl PK, Lotti VJ, Chang RS.. (1995) Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes., 38 (19): [PMID:7562905] [10.1021/jm00019a004] |
| 53. Bandurco V, Murray W, Gill A, Addo M, Lewis J, Wachter M, Hadden S, Underwood D, Cheung W. (1993) 1,3- And 1,5-bisbiphenylyl substituted 3-metcaptotriazoles as angiotensin II receptor antagonists, 3 (2): [10.1016/S0960-894X(01)80915-X] |
| 54. Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, van Meel JC, Wienen W, Hauel NH.. (1993) 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships., 36 (25): [PMID:8258826] [10.1021/jm00077a007] |
| 55. Chakravarty PK, Naylor EM, Chen A, Chang RS, Chen TB, Faust KA, Lotti VJ, Kivlighn SD, Gable RA, Zingaro GJ.. (1994) A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist., 37 (24): [PMID:7990105] [10.1021/jm00050a002] |
| 56. Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Patchett AA, Greenlee WJ.. (1993) Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles., 36 (26): [PMID:8277505] [10.1021/jm00078a013] |
| 57. Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Patchett AA, Greenlee WJ.. (1993) Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides., 36 (26): [PMID:8277506] [10.1021/jm00078a014] |
| 58. Palkowitz AD, Steinberg MI, Thrasher KJ, Reel JK, Hauser KL, Zimmerman KM, Wiest SA, Whitesitt CA, Simon RL, Pfeifer W.. (1994) Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists., 37 (26): [PMID:7799401] [10.1021/jm00052a010] |
| 59. Johannesson P, Lindeberg G, Tong W, Gogoll A, Synnergren B, Nyberg F, Karlén A, Hallberg A.. (1999) Angiotensin II analogues encompassing 5,9- and 5,10-fused thiazabicycloalkane tripeptide mimetics., 42 (22): [PMID:10579816] [10.1021/jm991089q] |
| 60. Norman MH, Smith HD, Andrews CW, Tang FL, Cowan CL, Steffen RP.. (1995) 4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists., 38 (23): [PMID:7473594] [10.1021/jm00023a006] |
| 61. Atwal KS, Ahmed SZ, Bird JE, Delaney CL, Dickinson KE, Ferrara FN, Hedberg A, Miller AV, Moreland S, O'Reilly BC.. (1992) Dihydropyrimidine angiotensin II receptor antagonists., 35 (25): [PMID:1469703] [10.1021/jm00103a014] |
| 62. Salimbeni A, Canevotti R, Paleari F, Poma D, Caliari S, Fici F, Cirillo R, Renzetti AR, Subissi A, Belvisi L.. (1995) N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists., 38 (24): [PMID:7490730] [10.1021/jm00024a008] |
| 63. Segarra V, Crespo MI, Pujol F, Beleta J, Doménech T, Miralpeix M, Palacios JM, Castro A, Martinez A.. (1998) Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds., 8 (5): [PMID:9871607] [10.1016/s0960-894x(98)00058-4] |
| 64. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T.. (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres., 39 (26): [PMID:8978851] [10.1021/jm960547h] |
| 65. Ellingboe JW, Antane M, Nguyen TT, Collini MD, Antane S, Bender R, Hartupee D, White V, McCallum J, Park CH.. (1994) Pyrido[2,3-d]pyrimidine angiotensin II antagonists., 37 (4): [PMID:8120871] [10.1021/jm00030a013] |
| 66. Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, García-Rafanell J, Forn J.. (1997) Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles., 40 (4): [PMID:9046346] [10.1021/jm9604383] |
| 67. Steinberg M, Palkowitz A, Thrasher K, Reel J, Zimmerman K, Whitesitt C, Simon R, Hauser K, Lifer S, Pfeifer W, Takeuchi K, Wiest S, Vasudevan V, Bermis K, Deeter J, Barnett C, Wilson T, Marshall W, Boyd D. (1994) Chiral recognition of the angiotensin II (AT1) receptor by a highly potent phenoxyproline octanoamide, 4 (1): [10.1016/S0960-894X(01)81121-5] |
| 68. Ashton WT, Cantone CL, Chang LL, Hutchins SM, Strelitz RA, MacCoss M, Chang RS, Lotti VJ, Faust KA, Chen TB.. (1993) Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles., 36 (5): [PMID:8496939] [10.1021/jm00057a009] |
| 69. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB.. (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy., 39 (3): [PMID:8576904] [10.1021/jm9504722] |
| 70. Carini DJ, Ardecky RJ, Ensinger CL, Pruitt JR, Wexler RR, Wong PC, Huang S, Aungst BJ, Timmermans PB. (1994) Nonpeptide angiotensin II receptor antagonists: the discovery of DMP 581 and DMP 811, 4 (1): [10.1016/S0960-894X(01)81123-9] |
| 71. Middlemiss D, Drew G, Ross B, Robertson M, Scopes D, Dowle M, Akers J, Cardwell K, Clark K, Coote S, Eldred C, Hamblett J, Hilditch A, Hirst G, Jack T, Montana J, Panchal T, Paton J, Shah P, Stuart G, Travers A. (1991) Bromobenzofurans : a new class of potent, non-peptide antagonists of angiotensin II, 1 (12): [10.1016/S0960-894X(01)81053-2] |
| 72. Krovat EM, Langer T.. (2003) Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification., 46 (5): [PMID:12593652] [10.1021/jm021032v] |
| 73. Soll R, Kinney W, Primeau J, Garrick L, McCaully R, Colatsky T, Oshiro G, Park C, Hartupee D, White V, McCallum J, Russo A, Dinish J, Wojdan A. (1993) 3-hydroxy-3-cyclobutene-1,2-dione: Application of novel carboxylic acid bioisostere to an in-vivo active non-tetrazole angiotensin-II antagonist, 3 (4): [10.1016/S0960-894X(01)81269-5] |
| 74. Bondensgaard K, Ankersen M, Thøgersen H, Hansen BS, Wulff BS, Bywater RP.. (2004) Recognition of privileged structures by G-protein coupled receptors., 47 (4): [PMID:14761190] [10.1021/jm0309452] |
| 75. Schmidt B, Lindman S, Tong W, Lindeberg G, Gogoll A, Lai Z, Thörnwall M, Synnergren B, Nilsson A, Welch CJ, Sohtell M, Westerlund C, Nyberg F, Karlén A, Hallberg A.. (1997) Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5., 40 (6): [PMID:9083479] [10.1021/jm960553d] |
| 76. Murray W, Lalan P, Gill A, Lee D, Falotico R, Lewis J, Addo M, Wachter M. (1994) Substituted lactam biphenyltetrazoles as angiotensin II mediated antihypertensives, 4 (1): [10.1016/S0960-894X(01)81127-6] |
| 77. Bali A, Bansal Y, Sugumaran M, Saggu JS, Balakumar P, Kaur G, Bansal G, Sharma A, Singh M.. (2005) Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists., 15 (17): [PMID:16039125] [10.1016/j.bmcl.2005.05.054] |
| 78. Breschi MC, Calderone V, Digiacomo M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Balsamo A.. (2004) NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs., 47 (23): [PMID:15509155] [10.1021/jm049681p] |
| 79. Johannesson P, Erdélyi M, Lindeberg G, Frändberg PA, Nyberg F, Karlén A, Hallberg A.. (2004) AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics., 47 (24): [PMID:15537355] [10.1021/jm049651m] |
| 80. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M.. (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist., 47 (24): [PMID:15537354] [10.1021/jm049715t] |
| 81. Berellini G, Cruciani G, Mannhold R.. (2005) Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists., 48 (13): [PMID:15974591] [10.1021/jm049024x] |
| 82. Ismail MA, Barker S, Abou el-Ella DA, Abouzid KA, Toubar RA, Todd MH.. (2006) Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists., 49 (5): [PMID:16509571] [10.1021/jm050232e] |
| 83. Breschi MC, Calderone V, Digiacomo M, Macchia M, Martelli A, Martinotti E, Minutolo F, Rapposelli S, Rossello A, Testai L, Balsamo A.. (2006) New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties., 49 (8): [PMID:16610806] [10.1021/jm0600186] |
| 84. Cappelli A, Pericot Mohr Gl, Giuliani G, Galeazzi S, Anzini M, Mennuni L, Ferrari F, Makovec F, Kleinrath EM, Langer T, Valoti M, Giorgi G, Vomero S.. (2006) Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds., 49 (22): [PMID:17064065] [10.1021/jm0603163] |
| 85. Xu JY, Zeng Y, Ran Q, Wei Z, Bi Y, He QH, Wang QJ, Hu S, Zhang J, Tang MY, Hua WY, Wu XM.. (2007) Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists., 17 (10): [PMID:17412584] [10.1016/j.bmcl.2007.02.042] |
| 86. Moda TL, Montanari CA, Andricopulo AD.. (2007) Hologram QSAR model for the prediction of human oral bioavailability., 15 (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060] |
| 87. Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.. (2008) Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems., 51 (7): [PMID:18318468] [10.1021/jm7011563] |
| 88. Shah DI, Sharma M, Bansal Y, Bansal G, Singh M.. (2008) Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives., 43 (9): [PMID:18158200] [10.1016/j.ejmech.2007.11.008] |
| 89. Guo XZ, Shi L, Wang R, Liu XX, Li BG, Lu XX.. (2008) Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring., 16 (24): [PMID:18976926] [10.1016/j.bmc.2008.10.040] |
| 90. Velázquez AM, Martínez L, Abrego V, Balboa MA, Torres LA, Camacho B, Díaz-Barriga S, Romero A, López-Castañares R, Angeles E.. (2008) Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives., 43 (3): [PMID:17582658] [10.1016/j.ejmech.2007.04.003] |
| 91. Kaur N, Kaur A, Bansal Y, Shah DI, Bansal G, Singh M.. (2008) Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists., 16 (24): [PMID:19013821] [10.1016/j.bmc.2008.10.056] |
| 92. Ohno O, Ye M, Koyama T, Yazawa K, Mura E, Matsumoto H, Ichino T, Yamada K, Nakamura K, Ohno T, Yamaguchi K, Ishida J, Fukamizu A, Uemura D.. (2008) Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension., 16 (16): [PMID:18672373] [10.1016/j.bmc.2008.03.056] |
| 93. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 94. García G, Rodríguez-Puyol M, Alajarín R, Serrano I, Sánchez-Alonso P, Griera M, Vaquero JJ, Rodríguez-Puyol D, Alvarez-Builla J, Díez-Marqués ML.. (2009) Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage., 52 (22): [PMID:19863054] [10.1021/jm9003957] |
| 95. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination., 53 (3): [PMID:20070106] [10.1021/jm901371v] |
| 96. Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, Shimada I, Takahashi H.. (2010) Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI., 53 (5): [PMID:20158191] [10.1021/jm901534d] |
| 97. Avdeef A, Tam KY.. (2010) How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?, 53 (9): [PMID:20373811] [10.1021/jm901846t] |
| 98. Mahalingam AK, Wan Y, Murugaiah AM, Wallinder C, Wu X, Plouffe B, Botros M, Nyberg F, Hallberg A, Gallo-Payet N, Alterman M.. (2010) Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition., 18 (12): [PMID:20493713] [10.1016/j.bmc.2010.03.064] |
| 99. Abrego VH, Martínez-Pérez B, Torres LA, Angeles E, Martínez L, Marroquín-Pascual JL, Moya-Hernández R, Amaro-Recillas HA, Rueda-Jackson JC, Rodríguez-Barrientos D, Rojas-Hernández A.. (2010) Antihypertensive and antiarrhythmic properties of a para-hydroxy[bis(ortho-morpholinylmethyl)]phenyl-1,4-DHP compound: comparison with other compounds of the same kind and relationship with logP values., 45 (10): [PMID:20705371] [10.1016/j.ejmech.2010.07.027] |
| 100. PubChem BioAssay data set, |
| 101. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 102. Naik P, Murumkar P, Giridhar R, Yadav MR.. (2010) Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective., 18 (24): [PMID:21071232] [10.1016/j.bmc.2010.10.043] |
| 103. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 104. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 105. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 106. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 107. Wenlock MC, Barton P, Luker T.. (2011) Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design., 21 (12): [PMID:21601448] [10.1016/j.bmcl.2011.04.133] |
| 108. Tukey RH, Strassburg CP.. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease., 40 (1): [PMID:10836148] [10.1146/annurev.pharmtox.40.1.581] |
| 109. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 110. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 111. Wang JL, Zhang J, Zhou ZM, Li ZH, Xue WZ, Xu D, Hao LP, Han XF, Fei F, Liu T, Liang AH.. (2012) Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists., 49 [PMID:22309912] [10.1016/j.ejmech.2012.01.009] |
| 112. Kim TW, Yoo BW, Lee JK, Kim JH, Lee KT, Chi YH, Lee JY.. (2012) Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists., 22 (4): [PMID:22264484] [10.1016/j.bmcl.2011.12.116] |
| 113. García G, Serrano I, Sánchez-Alonso P, Rodríguez-Puyol M, Alajarín R, Griera M, Vaquero JJ, Rodríguez-Puyol D, Alvarez-Builla J, Díez-Marqués ML.. (2012) New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers., 50 [PMID:22336384] [10.1016/j.ejmech.2012.01.043] |
| 114. Nie YY, Da YJ, Zheng H, Yang XX, Jia L, Wen CH, Liang LS, Tian J, Chen ZL.. (2012) Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect., 20 (8): [PMID:22410249] [10.1016/j.bmc.2012.02.003] |
| 115. Bai R, Wei Z, Liu J, Xie W, Yao H, Wu X, Jiang J, Wang Q, Xu J.. (2012) Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists., 20 (15): [PMID:22750010] [10.1016/j.bmc.2012.06.011] |
| 116. Zhang J, Wang JL, Zhou ZM, Li ZH, Xue WZ, Xu D, Hao LP, Han XF, Fei F, Liu T, Liang AH.. (2012) Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists., 20 (14): [PMID:22727371] [10.1016/j.bmc.2012.05.056] |
| 117. Agelis G, Resvani A, Durdagi S, Spyridaki K, Tůmová T, Slaninová J, Giannopoulos P, Vlahakos D, Liapakis G, Mavromoustakos T, Matsoukas J.. (2012) The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives., 55 [PMID:22889560] [10.1016/j.ejmech.2012.07.040] |
| 118. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 119. Soldner A, Benet LZ, Mutschler E, Christians U.. (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers., 129 (1): [PMID:10725273] [10.1038/sj.bjp.0703150] |
| 120. Borgnia MJ, Eytan GD, Assaraf YG.. (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity., 271 (1): [PMID:8621716] [10.1074/jbc.271.6.3163] |
| 121. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K.. (2002) Interaction of digoxin with antihypertensive drugs via MDR1., 70 (1): [PMID:11895100] [10.1016/s0024-3205(01)01494-1] |
| 122. Race JE, Grassl SM, Williams WJ, Holtzman EJ.. (1999) Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3)., 255 (1): [PMID:10049739] [10.1006/bbrc.1998.9978] |
| 123. Meanwell NA.. (2011) Synopsis of some recent tactical application of bioisosteres in drug design., 54 (8): [PMID:21413808] [10.1021/jm1013693] |
| 124. Da YJ, Yuan WD, Xin T, Nie YY, Ye Y, Yan YJ, Liang LS, Chen ZL.. (2012) Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects., 20 (24): [PMID:23122933] [10.1016/j.bmc.2012.09.065] |
| 125. Noorizadeh H, Noorizadeh M, Farmany A. (2012) Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS, 21 (12): [10.1007/s00044-012-9977-1] |
| 126. Jain A, Sharma R, Chaturvedi SC. (2013) A rational design, synthesis, characterization, and antihypertensive activities of some new substituted benzimidazoles, 22 (10): [10.1007/s00044-012-0462-7] |
| 127. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.. (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling., 56 (3): [PMID:23241029] [10.1021/jm301302s] |
| 128. PubChem BioAssay data set, |
| 129. Agelis G, Resvani A, Koukoulitsa C, Tůmová T, Slaninová J, Kalavrizioti D, Spyridaki K, Afantitis A, Melagraki G, Siafaka A, Gkini E, Megariotis G, Grdadolnik SG, Papadopoulos MG, Vlahakos D, Maragoudakis M, Liapakis G, Mavromoustakos T, Matsoukas J.. (2013) Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers., 62 [PMID:23376252] [10.1016/j.ejmech.2012.12.044] |
| 130. Yadav MR, Naik PP, Gandhi HP, Chauhan BS, Giridhar R.. (2013) Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted ligands for α1- and AII-receptors antagonism., 23 (13): [PMID:23683590] [10.1016/j.bmcl.2013.04.054] |
| 131. Zhang J, Wang JL, Yu WF, Zhou ZM, Tao WC, Wang YC, Xue WZ, Xu D, Hao LP, Han XF, Fei F, Liu T, Liang AH.. (2013) Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles., 69 [PMID:24007859] [10.1016/j.ejmech.2013.08.014] |
| 132. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.. (2013) Structure-based identification of OATP1B1/3 inhibitors., 83 (6): [PMID:23571415] [10.1124/mol.112.084152] |
| 133. Liu J, Liu Q, Yang X, Xu S, Zhang H, Bai R, Yao H, Jiang J, Shen M, Wu X, Xu J.. (2013) Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates., 21 (24): [PMID:24200932] [10.1016/j.bmc.2013.10.017] |
| 134. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 135. PubChem BioAssay data set, |
| 136. Zhu W, Da Y, Wu D, Zheng H, Zhu L, Wang L, Yan Y, Chen Z.. (2014) Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities., 22 (7): [PMID:24613628] [10.1016/j.bmc.2014.02.008] |
| 137. Iwamura A, Fukami T, Hosomi H, Nakajima M, Yokoi T.. (2011) CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay., 39 (5): [PMID:21321060] [10.1124/dmd.110.037259] |
| 138. Iwamura A, Fukami T, Hosomi H, Nakajima M, Yokoi T.. (2011) CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay., 39 (5): [PMID:21321060] [10.1124/dmd.110.037259] |
| 139. Cabaleiro T, Román M, Ochoa D, Talegón M, Prieto-Pérez R, Wojnicz A, López-Rodríguez R, Novalbos J, Abad-Santos F.. (2013) Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers., 41 (1): [PMID:23118328] [10.1124/dmd.112.046292] |
| 140. Han XF, He X, Wang M, Xu D, Hao LP, Liang AH, Zhang J, Zhou ZM.. (2015) Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center., 103 [PMID:26397395] [10.1016/j.ejmech.2015.09.010] |
| 141. Han X, Xue W, Hao L, Zhou Z. (2015) Synthesis and biological evaluation of 4-[(benzimidazol-1-yl) methyl]biphenyl-2-amides as dual angiotensin II and endothelin A receptor antagonists, 6 (8): [10.1039/C5MD00169B] |
| 142. Sallander J, Wallinder C, Hallberg A, Åqvist J, Gutiérrez-de-Terán H.. (2016) Structural determinants of subtype selectivity and functional activity of angiotensin II receptors., 26 (4): [PMID:26810314] [10.1016/j.bmcl.2015.10.084] |
| 143. Keller M, Kuhn KK, Einsiedel J, Hübner H, Biselli S, Mollereau C, Wifling D, Svobodová J, Bernhardt G, Cabrele C, Vanderheyden PM, Gmeiner P, Buschauer A.. (2016) Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples., 59 (5): [PMID:26824643] [10.1021/acs.jmedchem.5b01495] |
| 144. Bao X, Zhu W, Zhang R, Wen C, Wang L, Yan Y, Tang H, Chen Z.. (2016) Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs., 24 (9): [PMID:27004954] [10.1016/j.bmc.2016.03.028] |
| 145. Zhu W, Bao X, Ren H, Da Y, Wu D, Li F, Yan Y, Wang L, Chen Z.. (2016) N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation., 115 [PMID:27017546] [10.1016/j.ejmech.2016.03.021] |
| 146. Kritsi E, Matsoukas MT, Potamitis C, Karageorgos V, Detsi A, Magafa V, Liapakis G, Mavromoustakos T, Zoumpoulakis P.. (2016) Exploring new scaffolds for angiotensin II receptor antagonism., 24 (18): [PMID:27480029] [10.1016/j.bmc.2016.07.047] |
| 147. WHO Anatomical Therapeutic Chemical Classification, |
| 148. Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK.. (2017) Novel Glycoprotein VI Antagonists as Antithrombotics: Synthesis, Biological Evaluation, and Molecular Modeling Studies on 2,3-Disubstituted Tetrahydropyrido(3,4-b)indoles., 60 (1): [PMID:27996269] [10.1021/acs.jmedchem.6b01360] |
| 149. DrugMatrix, [10.6019/CHEMBL3885881] |
| 150. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump., 60 (3): [PMID:24799086] [10.1002/hep.27206] |
| 151. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 152. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 153. Vanderheyden PML, Benachour N.. (2017) Influence of the cellular environment on ligand binding kinetics at membrane-bound targets., 27 (16): [PMID:28666735] [10.1016/j.bmcl.2017.06.051] |
| 154. Meyer M, Foulquier S, Dupuis F, Flament S, Grimaud L, Henrion D, Lartaud I, Monard G, Grillier-Vuissoz I, Boisbrun M.. (2018) Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor., 158 [PMID:30223121] [10.1016/j.ejmech.2018.08.082] |
| 155. Unpublished dataset, |
| 156. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 157. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 158. McKinnell RM, Fatheree P, Choi SK, Gendron R, Jendza K, Olson Blair B, Budman J, Hill CM, Hegde LG, Yu C, McConn D, Hegde SS, Marquess DG, Klein U.. (2019) Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI)., 10 (1): [PMID:30655952] [10.1021/acsmedchemlett.8b00462] |
| 159. Cramer J, Sager CP, Ernst B.. (2019) Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group., 62 (20): [PMID:31083946] [10.1021/acs.jmedchem.9b00179] |
| 160. Babkov DA, Zhukowskaya ON, Borisov AV, Babkova VA, Sokolova EV, Brigadirova AA, Litvinov RA, Kolodina AA, Morkovnik AS, Sochnev VS, Borodkin GS, Spasov AA.. (2019) Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators., 29 (17): [PMID:31358465] [10.1016/j.bmcl.2019.07.035] |
| 161. Wu Z, Anh NTP, Yan YJ, Xia MB, Wang YH, Qiu Y, Chen ZL.. (2019) Design, synthesis and biological evaluation of AT1 receptor blockers derived from 6-substituted aminocarbonyl benzimidazoles., 181 [PMID:31369932] [10.1016/j.ejmech.2019.07.056] |
| 162. Wu Z, Bao XL, Zhu WB, Wang YH, Phuong Anh NT, Wu XF, Yan YJ, Chen ZL.. (2019) Design, Synthesis, and Biological Evaluation of 6-Benzoxazole Benzimidazole Derivatives with Antihypertension Activities., 10 (1): [PMID:30655944] [10.1021/acsmedchemlett.8b00335] |
| 163. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 164. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 165. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 166. Norman BH. (2020) Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies., 63 (20.0): [PMID:32511920] [10.1021/acs.jmedchem.0c00524] |
| 167. Chen J,Peng Z,Lu M,Xiong X,Chen Z,Li Q,Cheng Z,Jiang D,Tao L,Hu G. (2018) Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy., 28 (2): [PMID:29248299] [10.1016/j.bmcl.2017.07.001] |
| 168. Foster H,Wilson C,Philippou H,Foster R. (2020) Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis., 63 (21): [PMID:32463237] [10.1021/acs.jmedchem.0c00262] |
| 169. (2021) EUbOPEN Chemogenomics Library wave 1, [10.6019/CHEMBL4689842] |
| 170. Schoepf AM,Salcher S,Obexer P,Gust R. (2020) Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells., 195 [PMID:32272420] [10.1016/j.ejmech.2020.112258] |
| 171. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 172. EUbOPEN. (2022) EUbOPEN Chemogenomics Library wave 2 - DSF, [10.6019/CHEMBL5060014] |
| 173. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G.. (2022) Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators., 237 [PMID:35483322] [10.1016/j.ejmech.2022.114346] |
| 174. Li G, Cheng Y, Han C, Song C, Huang N, Du Y.. (2022) Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies., 13 (11.0): [PMID:36439976] [10.1039/d2md00206j] |
| 175. EUbOPEN. (2023) GPCR results for EUbOPEN Chemogenomics Library 3, [10.6019/CHEMBL5209801] |
| 176. Pillaiyar T, Meenakshisundaram S, Manickam M, Sankaranarayanan M.. (2020) A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery., 195 [PMID:32283298] [10.1016/j.ejmech.2020.112275] |
| 177. Danilenko AV, Volov AN, Volov NA, Platonova YB, Savilov SV.. (2023) Design, synthesis and biological evaluation of novel indole-3-carboxylic acid derivatives with antihypertensive activity., 90 [PMID:37236375] [10.1016/j.bmcl.2023.129349] |
| 178. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
| 179. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL.. (2019) Mapping human microbiome drug metabolism by gut bacteria and their genes., 570 (7762): [PMID:31158845] [10.1038/s41586-019-1291-3] |
